IDARUBICIN HYDROCHLORIDE

Post-LOE

idarubicin hydrochloride

Hikma

ANDAINTRAVENOUSSOLUTION

Approved

Oct 2012

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

IDARUBICIN HYDROCHLORIDE (idarubicin hydrochloride) by Hikma is dna, inhibiting nucleic acid synthesis, inhibiting topoisomerase ii activity, and producing dna-damaging free radicals. Approved for acute myeloid leukemia (aml) in adults. First approved in 2012.

Drug data last refreshed 18h ago

Mechanism of Action

DNA, inhibiting nucleic acid synthesis, inhibiting topoisomerase II activity, and producing DNA-damaging free radicals.

Indications (1)

acute myeloid leukemia (AML) in adults

Company

Worked on IDARUBICIN HYDROCHLORIDE at Hikma? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.